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Background: MTA2 gene belongs to metastasis associated family, and is highly expressed in some solid tumors,
including gastric cancer. Its biological function in gastric cancer is currently undefined.
Methods: Metastasis-associated tumor gene family 2 (MTA2) and transcription factor specificity protein 1 (Sp1)
expression were detected in 127 gastric cancer samples by immunohistochemistry staining. SGC-7901 and AGS
gastric cancer cell lines transfected by MTA2 shRNA was used for biological function investigation. Binding and
regulation activities of Sp1 on MTA2 promoter were investigated by chromatin immunoprecipitation and luciferase
reporter gene.
Results: The expression rate of MTA2 in gastric cancer tissues was 55.9% (71/127), and its expression was closely
related to the depth of tumor invasion, lymph nodes metastasis, and TNM staging. MTA2 knockdown in human
SGC-7901 and AGS gastric cancer cells significantly inhibited migration and invasion in vitro, and disrupted structure
of cytoskeleton. MTA2 knockdown also attenuated xenografts growth and lung metastasis in nude mice model.
MTA2 expression was positively correlated with transcription factor Sp1 in gastric cancer tissues (r = 0.326, P < 0.001).
Sp1 bound to human MTA2 gene promoter at region from -1043 bp to -843 bp. Transcriptional activity of MTA2
promoter could be enhanced by Sp1 overexpression.
Conclusions: MTA2 knockdown impairs invasion and metastasis of gastric cancer cells, and attenuates xenografts
growth in vivo. Sp1 regulates MTA2 expression at transcriptional level.
Keywords: Gastric cancer, MTA2, Cell invasion, Transcriptional regulation, Sp1Background
Gastric cancer is one of the major malignancies in main-
land of China, with high incidence and mortality [1]. The
newly diagnosed gastric cancer patients in China account
for 40% worldwide cases every year [2,3]. Furthermore,
over 80% gastric cancer patients in this developing country
are diagnosed at advanced stage, resulting in a relative
poor outcome [4,5].
Distant metastasis is the major cause of death for cancer
patients. Initiation of metastasis consists of multiple steps* Correspondence: jun_zj10977@163.com
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stated.and involves abundant molecules events [6,7]. Mecha-
nisms of metastasis in gastric cancer are still under investi-
gation. Metastasis-associated tumor gene family (MTA)
has three members, MTA1, MTA2 and MTA3. MTA1
overexpression was observed in some solid tumors, in-
cluding breast, esophageal, pancreatic, hepatocellular car-
cinoma [8], and correlated with cancer cell invasion and
metastasis [9,10]. MTA2 has high homology with MTA1
in protein alignment, and also consists in nucleosome
remodeling and histone deacetylase (NuDR) complex
[11,12]. These results suggested that function of MTA2
might be similar to MTA1. Currently, its biological func-
tion in gastric cancer is still unclear.
The regulation of MTA family has not been fully eluci-
dated. It was reported that mouse Mta2 gene was regu-
lated by transcription factor specificity protein 1 (Sp1)
[13]. Although amino acid sequences of MTA2 betweentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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sequences are different. Sp1 was found to be overexpressed
in gastric cancer tissues, and had positive correlation with
MTA2 [14-16]. Those results hinted potential regulatory
role of Sp1 in MTA2 transcription.
In present study, the biological function of MTA2 pro-
tein in gastric cancer was assessed both in vitro and
in vivo, the role of Sp1 in transcriptional regulation of hu-
man MTA2 gene promoter was also investigated.
Results
MTA2 protein was highly expressed in gastric cancer tissues
The results of immunohistochemistry staining revealed
that, the positive rate of MTA2 protein in gastric cancer
tissues was 55.9% (71/127). MTA2 protein was mainly lo-
calized in the nuclear of gastric cancer cells, and its ex-
pression was much more dominant in tumor tissues than
that in neighboring gastric mucosa (Figure 1A). MTA2
protein expression was closely related with depth of tumor
invasion (P = 0.003), lymph nodes metastasis (P = 0.019),
and TNM staging (P = 0.007), whereas no correlation with
Lauren’s classification and tumor differentiation (Table 1).
Patients with MTA2 expression had a shorter overall sur-
vival time with marginally significance (60 mos vs. 76 mos,
P = 0.078, Figure 1B). By multivariate analysis, TNM sta-
ging was an independent prognostic factor (P < 0.001, HR
2.165, 95% CI 1.612 to 2.909). However, no survival differ-
ence was observed in patients with different MTA2 status
in identical TNM staging (Additional file 1: Figure S1).
MTA2 knockdown attenuated migration and invasion of
gastric cancer cells
MTA2 expression in gastric cancer cell lines SGC-7901 and
AGS was knocked down by shRNA transfection, and cells
transfected by vector was identified as negative control
(Figure 2A). In proliferation assay, no significant differenceFigure 1 MTA2 in paired mucosa beside tumor and tumor tissues, an
mucosa beside tumor and tumor tissues from two patients (a, b and c, d) w
had a shorter median overall survival than those with MTA2 negative (60 mwas observed between MTA2 knockdown group and con-
trol group. In colony formation assay, the number of
clones was similar between two groups, but the size of
clones formed in MTA2 knockdown cells was smaller than
those in control group (Figure 2B).
The wound healing course of MTA2 knockdown group
was significantly slower than that in control group. Fur-
thermore, at the edge of scratch, pseudopodia of control
cells could extend perpendicular to the free space of
scratch, which was found in MTA2 knockdown group
(Figure 2C). For SGC-7901 cells, the numbers of cells
penetrating the membrane of chambers in both migra-
tion and invasion assays were significantly less in MTA2
knockdown group than those in control group (Migra-
tion: 3.0 ± 1.7 vs. 17.3 ± 4.5, P = 0.007; Invasion: 3.7 ± 1.5
vs. 54.0 ± 14.4, P = 0.004, Figure 2D), respectively. For
AGS cell line, the result of migration assay was similar
(2.7 ± 1.5 vs. 13.7 ± 2.1, P = 0.002, Figure 2D), and in inva-
sion assay, number of cells were low in both groups.
MTA2 expression in AGS/shMTA2 cells was rescued by
transient transfection of MTA2 plasmid. Migration ability
of AGS/shMTA2 cells was partially recovered (Additional
file 1: Figure S2).
MTA2 knockdown disturbed the structure of
actin cytoskeleton
In order to confirm the morphological changes observed
in wound healing assay, the structure of actin cytoskeleton
was observed. In MTA2 knockdown cells, the structure of
fibrous actin (F-actin) was less than cells in control group.
Cell morphology was changed from spindle to spherical
after MTA2 knockdown (Figure 3A). The expression of
CD24 and MYLK, genes related with cytoskeleton regula-
tion were assessed by qRT-PCR. These two genes were
found to be significantly reduced in MTA2 knockdown
cells than those in control group (Figure 3B).d survival curve of patients. A, MTA2 expression in paired gastric
ere detected by IHC (×100). B, Patients with MTA2 positive expression
os vs. 76 mos, p = 0.078).
Table 1 Correlation between MTA2 and
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lung metastasis
The growth rate of MTA2 knockdown SGC-7901 xeno-
grafts was slower than that in control group (P = 0.043,
Figure 4A), and the average tumor weight of xenografts
was also lower (0.82 ± 0.08 g vs. 2.12 ± 0.58 g, P = 0.021).
MTA2 expression in xenografts was detected both by west-
ern blot (Additional file 1: Figure S3) and IHC (Figure 4B).
Ki-67 expression was significantly reduced in MTA2 knock-
down group, while apoptosis index (3.3 ± 0.6% vs. 3.0 ±
1.0%, P = 0.643) and microvessel density were similar in
both groups (Figure 4B). In lung metastasis models, four
mice in control group (4/9) developed pulmonary metas-
tase (Figure 4C). Per contra, no mice were found to develop
lung metastasis in MTA2 knockdown group (0/9).MTA2 in gastric cancer tissues was related with
Sp1 expression
Both MTA2 and Sp1 protein had similar expression pat-
tern in gastric cancer tissues (Figure 5A). The expression
rate of MTA2 was significant higher in those concomi-
tantly with Sp1 expression (Table 2, P < 0.01). Positive cor-
relation was found between the expression of these two
proteins (r = 0.326, P < 0.001). Concomitant expression ofMTA2 and Sp1 was also observed in gastric cancer cell
lines (Additional file 1: Figure S4).Binding area of Sp1 on MTA2 promoter located at region
from -1043 bp to -843 bp
The results of ChIP assay in SGC-7901 cells demonstrated
that, PCR product could be amplified by primer1 (-1179 bp
to -843 bp) and primer1.2 (-1043 bp to -843 bp), rather
than other 3 pairs. To confirm the in vitro results, ChIP
assay was also performed using gastric cancer tissues with
Sp1 high expression. PCR product could also be amplified
by primer1.2 rather than primer1.1 (Figure 5B).Sp1 overexpression enhanced the transcriptional activity
of MTA2 promoter
Reporter plasmids were co-transfected into SGC-7901
cells with either Sp1 plasmid or vector. The activities of
pGL3-1179, pGL3-1042, pGL3-797 and pGL3-482 were
significantly elevated by Sp1 introduction, whereas the ac-
tivity of pGL3-117 was extremely low, and had no re-
sponse to Sp1 introduction (Figure 5C). Similar results
were also demonstrated in AGS cells (Figure 5C). MTA2
mRNA expression was increased after Sp1 overexpression
in MKN45 cells, whereas the protein level was not signifi-
cantly changed (Additional file 1: Figure S5).
To verify the transcriptional role of Sp1 in MTA2 pro-
moter, Sp1 specific siRNA was co-transfected into SGC-
7901 cells with pGL3-264, the reporter plasmid containing
Sp1 binding area. Luciferase activity was significantly re-
duced by siRNA transfection after 24 h (Figure 5D).Discussion
MTA2 is an essential part for NuRD complex and activ-
ity [17]. The pathological and biological characteristics
of MTA2 in malignancies were rarely reported. MTA2
overexpression was first described in cervical cancer
[11]. Hereafter, its aberrant expression was found in
ovarian epithelial cancer, hepatocellular cancer, non-
small cell lung cancer, and correlated with invasive phe-
notypes such as large tumor size, poor differentiation
and lymph node metastasis [18-20].
The results of this study validated the patterns of MTA2
expression in gastric cancer tissues as we previously
reported [16]. Whether MTA2 could be served as a prog-
nostic factor of gastric cancer was still unclear [20]. Pa-
tients with MTA2 expression had a trend of worse
outcome. However, survival analysis stratified by TNM
staging showed no difference between MTA2 positive or
negative groups (Additional file 1: Table S1). Therefore,
even MTA2 expression was found to be related with TNM
staging, it is still couldn’t be considered an independent
prognostic factor.
Figure 2 MTA2 knockdown inhibited cell migration and invasion in vitro. A, Protein and mRNA expression of MTA2 were detected in
shMTA2 stable transfected cells and negative control (NC). B, In vitro cell growth were analyzed by proliferation assay and colony formation assay.
C, Cell mobility was investigated by wound healing assay. D, Capabilities of migration and invasion were analyzed by Transwell assay (Migration:
without Matrigel; Invasion: coated by Matrigel).
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complicated, tumor cells break through the barrier of
normal tissue, invade into surrounding extracellular
matrix and circulation, then extravasate into distantorgans to form metastasis foci. Cell mobility and inva-
sion ability play important roles in these processes [7].
The results of present study revealed the role of MTA2
in regulating gastric cancer cell mobility and invasion.
Figure 3 MTA2 knockdown disturbed the structure of actin cytoskeleton. A, F-actin cytoskeleton structure was visualized by
immunofluorescence staining. B, Relative mRNA expression of CD24 and MYLK was detected by qRT-PCR.
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ities of mouse 4 T1 mammary tumor cells were reduced
after Mta2 gene interference [21]. These results indi-
cated that MTA2 might participate in the process of
tumor progression.
The mechanisms of MTA2 in regulating cancer cell
mobility and invasion were unclear. MTA2 was reported
to serve as a component of Twist complex, and partici-
pated in inhibition of E-cadherin gene transcription. InFigure 4 MTA2 knockdown reduced xenografts growth and lung met
7901/shMTA2 cells were measured every 7 days for four weeks. B, Expression
apoptosis was assessed by TUNEL assay. C, Lung metastasis of SGC-7901/Vectthis study, we found that knockdown of MTA2 gene ex-
pression could alter gastric cancer cell morphology and
disturb F-actin structure. Furthermore, reduced mRNA
expression of both CD24 and MYLK were found in
MTA2 knockdown cells. Cytoskeleton remolding is es-
sential for controlling cell motility and cancer invasion
[22]. Up-regulation of CD24 could increase actin cyto-
skeletal remolding dynamic and enhance contractile
forces to facilitate cancer cell invasion [23,24]. Myosinastasis of SGC-7901 cells. A, Xenografts of SGC-7901/NC and SGC-
of MTA2, Ki-67 and CD34 was detected by immunohistochemistry. Cell
or cells was detected by H.E. staining.
Figure 5 Sp1 enhance transcriptional activity of human MTA2 gene promoter. A, Expression of MTA2 (a × 100, c × 200) and Sp1 (b × 100,
d × 200) in gastric cancer tissues were detected by IHC. B, DNA fragment pulled down with Sp1 antibody from SGC-7901 cells was amplified by
PCR using P1 (-1179 bp ~ -843 bp), P2 (-948 bp ~ -671 bp), P3 (-559 bp ~ -301 bp), P1.1 (-1179 bp ~ -1023 bp) and P1.2 (-1043 bp ~ -843 bp). P1.1
(-1179 bp ~ -1023 bp) and P1.2 (-1043 bp ~ -843 bp) were used for gastric cancer tissue with Sp1 high expression. C, Luciferase reporters
containing five different length of MTA2 promoter were co-transfected with Sp1 plasmid into SGC-7901 and AGS cells. Relative luciferase activity
was detected, respectively. D, pGL3-264 luciferase reporter was co-transfected with siRNA-Sp1 into SGC-7901 cells, and relative luciferase activity
was detected. M: Marker; In: Input; P: Primer; NC: negative control.
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interaction with actin filaments, and promote cell pro-
trusion and contraction [25]. NuRD complex, which
MTA2 consists in, regulates gene expression by remoldingthe structure of nucleosome. Alteration of CD24 and
MYLK expression might be one of the mechanisms for
MTA2 to modulate cytoskeleton and participate in cell
invasion.
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cell growth in vitro seemed to be a paradox. MTA2
knockdown didn’t interfere gastric cancer cell growth in
proliferation assay, but colony formation was attenuated.
This divergence might be attributed to different culture
conditions. Cells adhered to culture plates in prolifera-
tion assay, whereas was suspended in agar during colony
formation. Adhesion to substratum is necessary for nor-
mal adhering cells survival and growth [26]. Tumor cells,
however, can survive and grow in adhesion absent or
anchorage-independent condition, which is important for
tumorigenesis as well as metastasis [27]. Colony formation
assay is a convenient assay to assess the capability of cell
growth in anchorage-independent condition, and is closely
related to the in vivo situation [28]. Attenuation of tumori-
genesis and metastasis in vivo validated the result of col-
ony formation assay, indicated that MTA2 knockdown
could impair the anchorage-independent growth of gastric
cancer cells. Exogenous expression of MTA2 in SaoS-2
cells could enhance cell growth in colony formation assay.
Reducing of p53 acetylation and expression after MTA2
overexpression suggested that p53 inhibition might be one
of the mechanisms of MTA2 regulating anchorage- inde-
pendent growth [29]. Increased p53 expression was also
found in MTA2 knockdown cells in this study (Additional
file 1: Figure S6).
Transcription factor Sp1 plays an important role in
physiological process and also in human cancer pro-
gression by regulating transcription of diverse down-
stream genes [30,31]. Concomitant expression of MTA2
and Sp1, and high GC-content sequence in proximal re-
gion of human MTA2 promoter, the potential Sp1 bind-
ing region [32], indicated that MTA2 might also be a
downstream gene of Sp1 in gastric cancer. The results
of ChIP and luciferase activity assays demonstrated that
Sp1 could bind to MTA2 promoter, and enhance its
transcriptional activity.
In ChIP assay, we found that the binding area of Sp1
on MTA2 promoter was at -1043 bp to -843 bp. How-
ever, promoter downstream of this fragment could also
be regulated by Sp1 introduction. The characteristics of
Sp1 might attribute to this phenomenon. As a critical
transcription factor, Sp1 can regulate the expression of
abundant genes, including many transcription factors,
and even itself [33]. Overexpression of Sp1 might trigger
the activities of some transcription factors, and increasedthe transcriptional activity of MTA2 promoter without
direct binding.
On the other hand, multiple transcription factors typic-
ally bind together and form a transcriptional complex
[34]. Alteration of one factor might not abrogate the func-
tion of the complex. Luciferase activity recovered at 48 h
after Sp1 knockdown suggested a compensation mechan-
ism might exist. Xia et al. reported that cooperation of
transcription factor ETS or existence of Sp3 might con-
tribute to stable Mta2 protein level in mouse ES cells after
Sp1 knockdown [13]. In our study, several transcription
factors’ binding sites were predicted in fragment from
-1042 bp to -797 bp, including AP-1, NF-1 and E2F which
were reported had interaction with Sp1 [30]. Although the
regulatory function of Sp1 on MTA2 promoter was dem-
onstrated in this study, the in-detailed mechanisms of
MTA2 transcription need to be further clarified.
In conclusion, aberrant expression of MTA2 in gastric
cancer cells participates in cell mobility and invasion.
Overexpression of Sp1 could regulate the transcriptional
activity of MTA2 promoter and might partially contrib-
ute to MTA2 expression in gastric cancer.
Materials and methods
Ethical statement
Written informed consent was obtained from all partici-
pants, and study protocol was approved by the ethics
committee of Ruijin Hospital, Shanghai Jiaotong Univer-
sity School of Medicine. All mouse experiments were ap-
proved (Permit#20110930) by the Animal Care and Use
Committee and conducted an accord with the Guide for
the Care and Use Laboratory Animals of Ruijin Hospital,
Shanghai Jiaotong University School of Medicine.
Patients and samples
Paraffin-embedded specimens from 127 gastric cancer pa-
tients underwent standard D2 resection, were collected
from Department of Surgery, Shanghai Ruijin Hospital. All
samples were pathologically confirmed as gastric adenocar-
cinoma. Clinicopathological data were reviewed, and were
listed in Additional file 1: Table S1. TNM staging classifica-
tion was based on criteria of American Joint Committee on
Cancer (AJCC, 6th edition). Overall survival was recorded
from 103 patients.
Cell lines and transfection
Gastric cancer cell lines SGC-7901, AGS, MKN45, BGC-
823 were purchased from Shanghai Institute of Biological
Sciences, Chinese Academy of Sciences. Hs746T was pur-
chased from ATCC. Cells were cultured by RPMI-1640
medium with 10% fetal calf serum at 37°C and 5% CO2.
Five shRNA plasmids targeting different regions of MTA2
mRNA were purchased from Sigma. Plasmid shRNA-74
had the strongest efficiency, and its interference sequence
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TAT CTG TCT CAT TCA AGA GGG-3′. Stable
transfected cells were selected by puromycin (5 μg/ml).
Luciferase reporter plasmids constructed by pGL3-Basic
vector (Promega) and truncated MTA2 promoters were
co-transfected with Sp1 plasmid (persevered in our in-
stitute) into SGC-7901 and AGS cells. Relative luciferase
activity was detected at 48 h after transfection by dual-
luciferase assay system (Promega). Ratio of reporter plas-
mids and control plasmid (pRL-TK, Promega) was 20:1.
The concentration of Sp1-siRNA (Invitrogen) transfected
into SGC-7901 cells was 50 nM. Lipofectamine 2000
(Invitrogen) was used as transfection regent.
Immunohistochemistry staining (IHC)
Immunohistochemistry staining was performed on
4 μm-thick slices following EnVision two-step procedure
of Dako REAL™ Envision™ Detection System (Dako).
Slides were incubated by primary antibodies including
MTA2 (1:200, Santa Cruz), Sp1 (1:200, Santa Cruz), Ki-
67 (1:50, Dako), and CD34 (1:150, Dako), respectively,
followed incubated by HRP labeled secondary antibody
and were visualized by diaminobenzidine.
Both MTA2 and Sp1 proteins were localized in cell nu-
clear stained as brownish granules. The expression status of
MTA2 and Sp1 was determined by product score of aver-
age percentage and intensity of positive cells under 5 ran-
dom high-power fields [14]. Score for percentage: <5% (0),
5%-25% (1), 25%-50% (2), 50%-75% (3), and >75% (4); for
intensity: no staining (0), light brown (1), brown (2), and
dark brown (3). For MTA2, score of 0 and ≥1 was defined
as negative and positive, respectively. For Sp1, score of ≤3
and >3 was defined as negative and positive, respectively.
Western blot
One hundred micrograms protein were fractionated by
10% SDS-PAGE gel and transferred to PVDF membranes.
PVDF membranes were blocked by 5% skim milk for 1 h,
then were incubated overnight at 4°C with primary anti-
bodies, including MTA2 (1:1000, BETHYL), Sp1 (1:500,
Santa cruz) and HDAC1 (1:1000, Cell signaling technol-
ogy). Fluorescent secondary antibodies (1:15000, LI-COR)
and infrared imaging system (LI-COR) were used to
visualize the protein bands.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
RNA was extracted by Trizol reagent method. Reverse tran-
scription in 20 μl-system was preformed following protocol
of Applied Biosystems. Primers for qRT-PCR were MTA2:
F-TGT ACC GGG TGG GAG ATT AC, R-TGA GGC
TAC TAG AAA TGT CCC TG; CD24: F-CTC CTA CCC
ACG CAG ATT TAT TC, R-AGA GTG AGA CCA CGA
AGA GAC; MYLK: F- CCC GAG GTT GTC TGG TTCAAA, R-GCA GGT GTA CTT GGC ATC GT. Quantita-
tive mRNA expression was measured by ABI Prism
7900HT sequence detection system (Applied Biosystems),
and relative mRNA expression was calculated by com-
parative Ct method.
In vitro proliferation and colony formation assay
One thousand cells per well were plated and adhered in
96-well plates. Cell growth curves were assessed by Cell
Counting Kit-8 (Dojindo) for 5 days. Dissolved agar was
used in colony formation assay. Two milliliter of 0.4% ~
0.6% agar was added into 6-well plate as bottom gel. One
thousand cells suspended in 4 ml of 0.2% diluted agar
were poured on bottom gel, and were cultured for 2 weeks.
MTT was used to staining.
Wound healing and transwell assay
Cells were plated in 12-well plates with concentration
more than 90%. Wounds were scratched by pipette tips
and photographed every 24 h. Suspended cells were
washed by PBS buffer. Serum-free medium was used
for cell culture.
In invasion assay, 100 μl of diluted Matrigel (BD Biosci-
ences) was used to coat the chambers’ membrane (8 μm for
24-well plate, Millipore). Fifty thousand cells in 100 μl
serum-free medium were added into the upper chambers,
with full medium in lower chambers, then, cultured for
48 h. For migration assay, cells were cultured for 24 h under
the same conditions without Matrigel. Cells were fixed by
10% formalin, and stained by 0.1% crystal violet, and were
photographed and counted by inverted microscope.
Immunofluorescence
Cells were seeded and cultured on glass slides. After 24 h,
cells were fixed by 4% paraformaldehyde for 30 min, pene-
trated by 0.1% Triton X-100 for 15 min, and blocked by 5%
BSA for 30 min. Then, cells was incubated with anti-actin
antibody (1:80, Acti-stain™ 555 Fluorecent Phalloidin, Cyto-
skeleton) for 45 min, and mounted by VECTASHIELD
Mounting Medium with DAPI (Vector Labs). The images
were obtained by inverted ZEISS LSM710 confocal micro-
scope (40× oil lens) (Carl Zeiss), with ZEN 2009 Light Edi-
tion software (Carl Zeiss).
Subcutaneous nude mouse xenografts
Eight 4-week-old male BALB/c nude mice (Institute of
Zoology, China Academy of Sciences) were randomly di-
vided into 2 groups (4 for each group). One million SGC-
7901/Vector or SGC-7901/shMTA2 cells in 100 μl PBS
were inoculated subcutaneously. Tumor nodules were
measured every 7 days after its length reached over 4 mm,
and was calculated by following formula: V = (Width2 ×
Length)/2 [35]. Xenografts were collected at 5th week for
immunohistochemistry staining and protein extraction.
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Twenty 4-week-old male BALB/c nude mice (Institute of
Zoology, China Academy of Sciences) were randomly di-
vided into 2 groups (10 for each group). One million
SGC-7901/Vector or SGC-7901/shMTA2 cells in 100 μl
PBS were injected by tail vein, respectively. One mouse
from each group was sacrificed at one month after injec-
tion to evaluate the metastasis formation. Two months
later, all mice were sacrificed. Pulmonary metastases
were checked by gross specimens and microscopy.
Chromatin immunoprecipitation (ChIP)
The ChIP assay was performed following the protocol of
chromatin immunoprecipitation kit (Millipore). Protein
and DNA was crosslinked by formaldehyde, extracted by
SDS lysis buffer, and sheared by sonication. Sp1 antibody
(Santa Cruz) was used in immunoprecipitation. After puri-
fication of precipitated DNA, PCR was performed. The
primers used for PCR were listed in Additional file 1:
Table S2. PCR products were fractionated by gel electro-
phoresis and photographed.
Luciferase reporter plasmid, site specific mutagenesis and
promoter activity analysis
Primers for amplification of MTA2 promoter were listed
in Additional file 1: Table S3, with Kpn I site at 5′ end of
forward primer and Bgl II site at reverse primer. MTA2
promoter fragments were amplified from human genomic
DNA, and were inserted into pGL3-Basic vector. Six re-
porter plasmids were constructed and named as pGL3-
1179, pGL3-1042, pGL3-797, pGL3-482, pGL3-117 and
pGL3-264. Single-tube luminometer (Promega) was used
for dual-luciferase reporter assay (Promega) following
the manual.
Statistics
Chi-square test was used to analyze the categorical vari-
ables. Correlation between MTA2 and Sp1 expression was
analyzed by Spearman test. Log-rank test in Kaplan-Meier
method and Cox regression test was used to assess patients’
outcome and prognostic factors. Independent-samples t test
was used in quantitive data analysis. P-value <0.05 was con-
sidered as statistical significant. All tests were preformed by
SPSS 13.0 software (SPSS Inc.).Additional file
Additional file 1: Figure S1. Survival curve of Patients. Patients have
no survival difference with different MTA2 status in identical TNM staging.
Figure S2. MTA2 expression and migration ability of AGS/shMTA2 cells.
MTA2 expression was down-regulated in AGS/shMTA2 cells and was
rescued by transient transfection of MTA2 plasmid. Migration ability of
AGS/shMTA2 cells was partially recovered. Figure S3. MTA2 expression in
xenografts was detected by western blot. MTA2 expression was down-
regulated in xenografts of SGC-7901/shMTA2 cells. Figure S4. Expressionof MTA2 and Sp1 in gastric cancer cell lines. Concomitant expression of
MTA2 and Sp1 was observed in gastric cancer cell lines. Figure S5. MTA2
mRNA and protein expressions in Sp1 over-expressed MKN45 cells. MTA2
mRNA expression was increased after Sp1 overexpression in MKN45 cells,
whereas the protein level was not significantly changed. Figure S6. p53
expression in MTA2 knockdown cells. p53 expression was increased in
SGC-7901/shMTA2 and AGS/shMTA2 cells. Table S1. Clinicopathological
characteristics of 127 gastric cancer patients. Table S2. Primers for PCR in
chromatin immunoprecipitation. Table S3. Primers for construction of
luciferase reporter plasmid.
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